1. Medtech Insight
  2. >>Business
  3. >>Deals

Acutus Announces Four Deals To Expand Its Reach Into Electrophysiology

 
• By Reed Miller

Acutus announced a deal to acquire Rhythm Xience, and new strategic partnerships with Peerbridge Health, Cardiac Designs and MedFact, to offer more electrophysiology products that complement its AcQMap multi-electrode electrophysiology mapping catheter system.

Acutus
Real-time map of electrical activity in the heart created by AcQMap • Source: Acutus Medical

Acutus Medical Inc., which markets the AcQMap multi-electrode electrophysiology mapping system, will acquire Rhythm Xience, which makes devices to help electrophysiology catheters cross the heart’s septum, the companies announced on 9 May.

On the same day, Acutus also announced strategic partnerships with monitoring companies Peerbridge Health and Cardiac Designs, and a deal with MedFact to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Synchron And Apple Team Up To Use ‘Mind-Thought Connection’ To Control iPhones, iPads

 
• By Marion Webb

Apple and Synchron are teaming up to develop technologies that will one day allow people who can’t use their hands or voice to control iPhones, iPads and other Apple devices by using only their thoughts.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Danaher Faces $350M Tariff Hit, But Says It’s Ready To Absorb The Blow

 
• By Shubham Singh

Despite Danaher’s confident outlook, the company acknowledged near-term profitability fluctuations, particularly in the second quarter. Matt McGrew, Danaher’s CFO, clarified during the company’s first-quarter earnings call on 22 April, that expected operating margin softness in the second quarter – forecast at 25.5% – was not related to tariffs, but to seasonal dynamics in its respiratory diagnostics business.